Clearmind reports improved nasal retention for its MEAI drug formulation

Go back to Clearmind reports improved nasal retention for its MEAI drug formulation

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI

July 16, 2026 9:30 AM EDT

Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5Methoxy2aminoindane). Leveraging a nasal drugdelivery system, the new formulation demonstrated markedly improved nasal residence characteristics compared with a standard MEAI solution.

Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearminds strategy of developing differentiated, nextgeneration treatments for... More